Clinical Trial Update: Testing the PD-1 Inhibitor Pembrolizumab as Maintenance Therapy After Initial Chemotherapy in Metastatic Bladder Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial updating pembrolizumab as maintenance therapy after initial chemotherapy in metastatic bladder cancer; study completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Urothelial Carcinoma

Drugs mentioned

• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Matthew Galsky | Conditions: Urothelial Carcinoma, Bladder Cancer | Phase 2 | Status: COMPLETED | Results posted: 2022-09-30